Clinical Trial Update: A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) [Phase 3]

View source ↗

Summary

Phase 3 trial (EPPIC-1) evaluating AST-120 to prevent progression of chronic kidney disease has completed and posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• AST-120 (AST-120)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-03-02